Product Images Tiagabine Hydrochloride

Tiagabine Hydrochloride Tablets are contained in a 30-tablet bottle, with each tablet containing 12mg of USP Tiagabine Hydrochloride. The usual dosage should be determined by the accompanying package insert. The pharmacist should dispense in a tightly sealed container and advise patients to observe the medication guide. The contact information for Northstar Rx LLC is provided for inquiries. The medicine is manufactured in India by MSN Laboratories Private Limited.*

This is a description of Tiagabine Hydrochloride Tablets. The tablets come in a package of 30 and each contains 16 mg of Tiagabine Hydrochloride, USP. The accompanying package insert contains information on the recommended dosage of the medication. The tablets should be stored in a cool, dry place and should not be used if the package is damaged. They should be dispensed in a USP-approved container. The medication is manufactured in India by MSN Laboratories Private Limited and is distributed by Northstar Rx LLC in Memphis, TN. The NDC code for this product is 16714-154-01.*

This is a medication information label for Tiagabine Hydrochloride Tablets usually dosed at 2mg for patients. It also specifies not to accept the medication if the seal is broken or missing and to dispense in a light-resistant container. The manufacturer is Nortstar Rx LLC in Memphis, TN, and the medication is made in India. A medical guide is available for patients, and the NDC code for this medication is 16714-151-01.*

Tiagabine Hydrochloride Tablets are a prescription medicine containing 4mg of agabine hydrochloride, USP. Follow the dosage instructions provided on the package insert for proper use. Make sure not to accept the medication if the seal over the bottle opening is broken or missing. Keep it in a tightly sealed, light-resistant container. Medication guides are available from the pharmacist. Tiagabine Hydrochloride Tablets are manufactured by Nakoron ki tych oot MSN Laboraloris Private Limited in India and distributed by Northstar Rx LLC in Memphis, TN.*

The text describes a figure labeled "Figure 1" which displays the results of "Study 1" in relation to the reduction of partial seizure rates. The figure shows two bars representing different treatments: "Tiagabine Hydrochloride 32-56 mg/day" and "Placebo". The vertical axis represents the percentage of patients while the horizontal axis shows the level of improvement over time. The figure includes three levels of change: improvement, no change, and worsening.*

This text provides a visualization of the results obtained from Study 3 regarding the reduction in partial seizure rate. The figure shows percentages ranging from 100% to -250%, with increments of 50%. The chart compares the effectiveness of the placebo with Tiagabine hydrochloride taken three times a day at a dose of 10 mg. The chart also displays the improvement, no change, or worsening of patients receiving the medication or placebo.*